NOVATREMA BIOTECH PRIVATE LIMITED

In their own words

Novatrema Biotech Pvt. Ltd. is a pharmaceutical startup focused on leveraging artificial intelligence to bring innovation, sustainability, and efficiency into the healthcare and life sciences ecosystem. The company aims to address pressing challenges faced by pharmaceutical companies in forecasting demand, managing inventory, and optimizing market reach in a highly dynamic and complex industry. Factors such as seasonal diseases, regulatory shifts, competitive launches, and changing healthcare needs make accurate forecasting and timely distribution difficult. Traditional models fall short in addressing this complexity, often resulting in overproduction, stockouts, increased costs, and limited access to essential medicines, especially in underserved regions. To solve this, Novatrema Biotech Pvt. Ltd. has developed an AI-based forecasting and decision-support system that integrates historical sales data, prescription trends, external health data, disease outbreak patterns, demographic statistics, and marketing inputs to better predict future demand for pharmaceutical products. These insights enable the company to align its manufacturing, pricing, marketing, and distribution strategies with real-time market conditions. By deploying machine learning models, the startup can anticipate demand across geographies and product lines, ensuring a consistent supply of essential drugs while reducing wastage and inventory holding costs. This approach enables faster decision-making and smarter allocation of resources, contributing to business growth and public health improvement. The innovation lies in the use of data science not only for business optimization but also for societal good. For example, by predicting outbreaks of diseases like malaria and dengue, or identifying regions at high risk of diabetes or nutritional deficiencies, Novatrema Biotech can guide targeted production and distribution strategies. These insights can help strengthen national health infrastructure.

Written by the company on its public Startup India profile. Not verified by us.